Dapagliflozin reduces hepatic and visceral fat in type-2 diabetes patients with non-alcoholic fatty liver disease. Phrueksotsai S, Pinyopornpanish K, Euathrongchit J, Leerapun A, et al. J Gastroenterol Hepatol 2021 Jun 15. doi: 10.1111/jgh.15580.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Phrueksotsai S, Pinyopornpanish K, Euathrongchit J, Leerapun A, et al. Dapagliflozin reduces hepatic and visceral fat in type-2 diabetes patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2021 Jun 15. doi: 10.1111/jgh.15580.
PMID: 34129252